Paul Wadwa, MD

Provider's Specialties

Endocrinology - Pediatric

Community Provider

Provider's location(s)

View map

Patient ratings

Patient ratings and reviews are not available

Why?

Barbara Davis Center for Childhood Diabetes - Specialty Clinic

(303)724-2323

Insurance plans accepted

We participate with most major health insurance plans and national transplant networks.

View the full list

Prepare for your visit

We want to make sure you know what to expect before you arrive.

See the checklist

Get to know Paul Wadwa, MD

Conditions Treated

Type 1 Diabetes

Languages spoken

English

Experience and background

Type 1 Diabetes, Clinical trials in type 1 diabetes, Telemedicine, artificial pancreas technology

Undergraduate 1992

Northwestern University (IL)

Medical Education 1996

Northwestern University The Feinberg School of Medicine

Internship 1997

Nationwide Children's Hospital/Ohio State University Program

Residency 2000

Nationwide Children's Hospital/Ohio State University Program

Fellowship 2003

Cincinnati Children's Hospital Medical Center Program

For Patients:
My primary research focus is on the development of the artificial pancreas for patients with type 1 diabetes. I am involved in many clinical research studies with the goal of advancing artificial pancreas technology. I am also engaged in clinical trials of new therapeutic agents as well as research describing the effects of a clinical telemedicine program on diabetes control for youth with type 1 diabetes. My hope is that the research I am involved with will greatly improve the tools available to optimize control and reduce the burden of diabetes for patients locally and beyond.

For Referring Providers:
Dr. Wadwa’s research primarily focuses on the development of the artificial pancreas. He is engaged as a site PI and as a co-investigator for several NIH-sponsored and industry- sponsored clinical research studies with the goal of advancing artificial pancreas technology. Dr. Wadwa is also engaged in clinical trials of new therapeutic agents as well as research describing the effects of a clinical telemedicine program on glycemic control in pediatric type 1 diabetes patients.